First-in-human study of naporafenib (LXH254) with or without spartalizumab in adult patients with advanced solid tumors harboring MAPK signaling pathway alterations - Janku, Filip; Kim, Tae Min; Iyer, Gopakumar; Spreafico, Anna; Elez, Elena; de Jonge, Maja; Yamamoto, Noboru; van der Wekken, Anthonie J.; Ascierto, Paolo Antonio; Maur, Michela; Marmé, Frederik; Kiladjian, Jean-Jacques; et al. (European journal of cancer, 2024)
Online veröffentlicht: 20. November 2023